The heart of earnings season is upon us, as numerous companies provide updates on their firm’s performance over the past quarter. Of course, beating revenue and/or earnings estimates can positively affect a company’s financial outlook and share price, so it’s important for investors to stay tuned in right now.
A few key companies released impressive quarterly earnings reports Tuesday morning, and they look to have the potential to stir up investor interest in the near future. These earnings reports not only demonstrate the past quarter’s solid performance, but they also preview its financial outlook over its next operational quarter.
Check out these 3 companies that just performed extremely well this earnings season:
1. Caterpillar, Inc. (CAT – Free Report)
Caterpillar posted an impressive earnings surprise of 18.25% with adjusted earnings per share of $1.49, which compares favorably to the Zacks Consensus Estimate of $1.26. Caterpillar’s reported earnings are good for an astounding 37% year-over-year increase, driven by the company’s disciplined cost-control efforts. Also, Caterpillar reported revenues of $11.3 billion, which beat the Zacks Consensus Estimate of $10.9 billion and represents 9.6% year-over-year growth. This impressive revenue growth was caused by a 25% rise in Asia Pacific construction sales, as well as 7% gain in North America.
Caterpillar’s earnings report also included full-year revenue guidance in the range of $42-$44 billion, which is an increase from the previously-expected range of $38-$41 billion. Additionally, Caterpillar now projects earnings of $5.00 per share, up substantially from its previous prediction of $3.75. Caterpillar currently sports a Zacks Rank #2 (Buy).
2. Eli Lilly and Company (LLY – Free Report)
Eli Lilly and Company reported adjusted earnings per share of $1.11, which surpassed the Zacks Consensus Estimate of $1.04 by a solid 6.73%. Eli Lilly’s earnings demonstrate strong year-over-year growth of 29.06%. Furthermore, the company posted revenues of $5.82 billon, which surpassed the Zacks Consensus Estimate of $5.59 billion by a respectable 4.11%. The company’s reported revenue presents year-over-year growth of 7.8%. Revenue inside the U.S. increased by 15%, primarily due to high realized prices for several of its products, such as Cialis, Forteo, and Alimta.
No Comments